TCA
STOK icon

Troluce Capital Advisors’s Stoke Therapeutics STOK Stock Holding History

Troluce Capital Advisors’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.2M Sell
496,416
-156,384
-24% -$5.02M 1.67% 12
2026
Q1 		$21.3M Buy
+652,800
New +$21.4M 1.3% 27

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Troluce Capital Advisors's STOK Position: Q2 2026 in Review

Troluce Capital Advisors reduced its Stoke Therapeutics (STOK) stake by 24% in Q2 2026, selling an estimated $5.02M and leaving 496,416 shares worth $16.2M. The position accounts for 1.67% of the portfolio, ranked #12.

Troluce Capital Advisors first reported a position in STOK in Q1 2026 and has held it in 2 quarters since. The position peaked at $21.3M in Q1 2026. 198 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Troluce Capital Advisors held 496,416 shares of Stoke Therapeutics worth $16.2M as of Q2 2026.
  • Troluce Capital Advisors sold 156,384 Stoke Therapeutics shares in Q2 2026, an estimated $5.02M.
  • Stoke Therapeutics made up 1.67% of Troluce Capital Advisors's portfolio in Q2 2026, its #12 holding.
  • Troluce Capital Advisors first reported a position in Stoke Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Troluce Capital Advisors's Stoke Therapeutics position peaked at $21.3M in Q1 2026.
  • 198 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Troluce Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.